Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Higher satisfaction with an alternative collection device for stool sampling in colorectal cancer screening with fecal immunochemical test: a cross-sectional study

Authors: Hye Young Shin, Mina Suh, Kui Son Choi, Sang-Hyun Hwang, Jae Kwan Jun, Dong Soo Han, You Kyoung Lee, Jae Hwan Oh, Chan Wha Lee, Do-Hoon Lee

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Identifying preferences for stool collection devices may help increase uptake rates for colorectal cancer screening via fecal immunochemical test (FIT). This study surveyed satisfaction with different devices utilized to collect stool samples for FIT: a conventional container and a sampling bottle (Eiken OC-Sensor).

Methods

This cross-sectional study was conducted at the National Cancer Center, Korea. Participants aged 50–74 years who used either a conventional container or a sampling bottle to collect a stool sample for FIT were asked to complete a questionnaire designed to survey their satisfaction with the stool collection process and their intentions to undergo FIT in subsequent screening rounds. In total, 1657 participants (1224 conventional container, 433 sampling bottle) were included for analysis.

Results

Satisfaction with the sampling bottle was higher than that with the conventional container (79.9% vs.73.0%, p = 0.005, respectively; aOR = 1.52, 95% CI: 1.16–2.00). Participants satisfied with the sampling bottle were more likely to be female, be of younger age (50–64 years old), have higher household income, and have prior experience with FIT. Intentions to undergo subsequent screening were stronger among those given the sampling bottle than those given the conventional container (aOR = 1.78, 95% CI: 1.28–2 .48).

Conclusions

Satisfaction with the stool collection process was higher with the sampling bottle. However, additional studies are needed to validate whether the increased satisfaction and stronger intentions to undergo subsequent screening with the sampling bottle could actually lead to increased uptake in subsequent rounds, along with analysis of the device’s cost effectiveness.
Appendix
Available only for authorised users
Literature
1.
go back to reference Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed
2.
go back to reference Chiu H-M, Chang L-C, Hsu W-F, Chou C-K, Wu M-S. Non-invasive screening for colorectal cancer in Asia. Best Pract Res Clin Gastroenterol. 2015;29:953–65.CrossRefPubMed Chiu H-M, Chang L-C, Hsu W-F, Chou C-K, Wu M-S. Non-invasive screening for colorectal cancer in Asia. Best Pract Res Clin Gastroenterol. 2015;29:953–65.CrossRefPubMed
3.
go back to reference Jung K-W, Won Y-J, Oh C-M, Kong H-J, Lee DH, Lee KH. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 2017;49:292–305.CrossRefPubMedPubMedCentral Jung K-W, Won Y-J, Oh C-M, Kong H-J, Lee DH, Lee KH. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 2017;49:292–305.CrossRefPubMedPubMedCentral
4.
go back to reference Jin P, Wu ZT, Li SR, Li SJ, Wang JH, Wang ZH, et al. Colorectal cancer screening with fecal occult blood test: A 22-year cohort study. Oncol Lett. 2013;6:576–82.CrossRefPubMedPubMedCentral Jin P, Wu ZT, Li SR, Li SJ, Wang JH, Wang ZH, et al. Colorectal cancer screening with fecal occult blood test: A 22-year cohort study. Oncol Lett. 2013;6:576–82.CrossRefPubMedPubMedCentral
5.
go back to reference Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366:697–706.CrossRefPubMed Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366:697–706.CrossRefPubMed
7.
go back to reference Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64:1637–49.CrossRefPubMed Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64:1637–49.CrossRefPubMed
8.
go back to reference Suh M, Song S, Cho HN, Park B, Jun JK, Choi E, et al. Trends in participation rates for the National Cancer Screening Program in Korea, 2002-2012. Cancer Res Treat. 2017;49:790–7.CrossRef Suh M, Song S, Cho HN, Park B, Jun JK, Choi E, et al. Trends in participation rates for the National Cancer Screening Program in Korea, 2002-2012. Cancer Res Treat. 2017;49:790–7.CrossRef
9.
go back to reference Chambers JA, Callander AS, Grangeret R, O’Carroll RE. Attitudes towards the Faecal Occult Blood Test (FOBT) versus the Faecal Immunochemical Test (FIT) for colorectal cancer screening: perceived ease of completion and disgust. BMC Cancer. 2016;16:96.CrossRefPubMedPubMedCentral Chambers JA, Callander AS, Grangeret R, O’Carroll RE. Attitudes towards the Faecal Occult Blood Test (FOBT) versus the Faecal Immunochemical Test (FIT) for colorectal cancer screening: perceived ease of completion and disgust. BMC Cancer. 2016;16:96.CrossRefPubMedPubMedCentral
10.
go back to reference Hol L, de Jonge V, Van Leerdam M, van Ballegooijen M, Looman C, Van Vuuren A, et al. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Eur J Cancer. 2010;46:2059–66.CrossRefPubMed Hol L, de Jonge V, Van Leerdam M, van Ballegooijen M, Looman C, Van Vuuren A, et al. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Eur J Cancer. 2010;46:2059–66.CrossRefPubMed
11.
go back to reference Power E, Miles A, Von Wagner C, Robb K, Wardle J. Uptake of colorectal cancer screening: system, provider and individual factors and strategies to improve participation. Future Oncol. 2009;5:1371–88.CrossRefPubMed Power E, Miles A, Von Wagner C, Robb K, Wardle J. Uptake of colorectal cancer screening: system, provider and individual factors and strategies to improve participation. Future Oncol. 2009;5:1371–88.CrossRefPubMed
12.
go back to reference Logan RF, Patnick J, Nickerson C, Coleman L, Rutter MD, von Wagner C. Outcomes of the bowel cancer screening programme (BCSP) in England after the first 1 million tests. Gut. 2012;61(10):1439–46.CrossRefPubMed Logan RF, Patnick J, Nickerson C, Coleman L, Rutter MD, von Wagner C. Outcomes of the bowel cancer screening programme (BCSP) in England after the first 1 million tests. Gut. 2012;61(10):1439–46.CrossRefPubMed
13.
go back to reference Klabunde C, Blom J, Bulliard J-L, Garcia M, Hagoel L, Mai V, et al. Participation rates for organized colorectal cancer screening programmes: an international comparison. J Med Screen. 2015;22(3):119–26.CrossRefPubMed Klabunde C, Blom J, Bulliard J-L, Garcia M, Hagoel L, Mai V, et al. Participation rates for organized colorectal cancer screening programmes: an international comparison. J Med Screen. 2015;22(3):119–26.CrossRefPubMed
14.
go back to reference Park B, Choi KS, Lee YY, Jun JK, Seo HG. Cancer screening status in Korea, 2011: results from the Korean national cancer screening survey. Asian Pac J Cancer Prev. 2012;13:1187–91.CrossRefPubMed Park B, Choi KS, Lee YY, Jun JK, Seo HG. Cancer screening status in Korea, 2011: results from the Korean national cancer screening survey. Asian Pac J Cancer Prev. 2012;13:1187–91.CrossRefPubMed
15.
go back to reference Chubak J, Bogart A, Fuller S, Laing SS, Green BB. Uptake and positive predictive value of fecal occult blood tests: a randomized controlled trial. Prev Med. 2013;57:671–8.CrossRefPubMed Chubak J, Bogart A, Fuller S, Laing SS, Green BB. Uptake and positive predictive value of fecal occult blood tests: a randomized controlled trial. Prev Med. 2013;57:671–8.CrossRefPubMed
16.
go back to reference Ellis RJ, Wilson S, Holder RL, McManus RJ. Different faecal sampling methods alter the acceptability of faecal occult blood testing: a cross sectional community survey. Eur J Cancer. 2007;43:1437–44.CrossRefPubMed Ellis RJ, Wilson S, Holder RL, McManus RJ. Different faecal sampling methods alter the acceptability of faecal occult blood testing: a cross sectional community survey. Eur J Cancer. 2007;43:1437–44.CrossRefPubMed
17.
go back to reference Shin HY, Suh M, Baik HW, Choi KS, Park B, Jun JK, et al. The effect of changing stool collection processes on compliance in nationwide organized screening using a fecal occult blood test (FOBT) in Korea: study protocol for a randomized controlled trial. Trials. 2014;15(1):461.CrossRefPubMedPubMedCentral Shin HY, Suh M, Baik HW, Choi KS, Park B, Jun JK, et al. The effect of changing stool collection processes on compliance in nationwide organized screening using a fecal occult blood test (FOBT) in Korea: study protocol for a randomized controlled trial. Trials. 2014;15(1):461.CrossRefPubMedPubMedCentral
18.
go back to reference Vilkin A, Rozen P, Levi Z, Waked A, Maoz E, Birkenfeld S, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005;100:2519–25.CrossRefPubMed Vilkin A, Rozen P, Levi Z, Waked A, Maoz E, Birkenfeld S, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005;100:2519–25.CrossRefPubMed
19.
go back to reference Denters MJ, Deutekom M, Bossuyt PM, Fockens P, Dekker E. A feces collection paper does not enhance participation in a fecal immunochemical test-based colorectal cancer screening program: randomized clinical trial. Eur J Cancer Prev. 2013;22:299–304.CrossRefPubMed Denters MJ, Deutekom M, Bossuyt PM, Fockens P, Dekker E. A feces collection paper does not enhance participation in a fecal immunochemical test-based colorectal cancer screening program: randomized clinical trial. Eur J Cancer Prev. 2013;22:299–304.CrossRefPubMed
20.
go back to reference Chapple A, Ziebland S, Hewitson P, McPherson A. What affects the uptake of screening for bowel cancer using a faecal occult blood test (FOBt): a qualitative study. Soc Sci Med. 2008;66:2425–35.CrossRefPubMed Chapple A, Ziebland S, Hewitson P, McPherson A. What affects the uptake of screening for bowel cancer using a faecal occult blood test (FOBt): a qualitative study. Soc Sci Med. 2008;66:2425–35.CrossRefPubMed
21.
go back to reference Worthley DL, Cole SR, Esterman A, Mehaffey S, Roosa N, Smith A, et al. Screening for colorectal cancer by faecal occult blood test: why people choose to refuse. Intern Med. 2006;36:607–10.CrossRef Worthley DL, Cole SR, Esterman A, Mehaffey S, Roosa N, Smith A, et al. Screening for colorectal cancer by faecal occult blood test: why people choose to refuse. Intern Med. 2006;36:607–10.CrossRef
22.
go back to reference Clarke N, McNamara D, Kearney PM, O'Morain CA, Shearer N, Sharp L. The role of area-level deprivation and gender in participation in population-based faecal immunochemical test (FIT) colorectal cancer screening. Prev Med. 2016;93:198–203.CrossRefPubMed Clarke N, McNamara D, Kearney PM, O'Morain CA, Shearer N, Sharp L. The role of area-level deprivation and gender in participation in population-based faecal immunochemical test (FIT) colorectal cancer screening. Prev Med. 2016;93:198–203.CrossRefPubMed
23.
go back to reference Greiner KA, Daley CM, Epp A, James A, Yeh H-W, Geana M, et al. Implementation intentions and colorectal screening screening: a randomized trial in safety-net clinics. Am J Prev Med. 2014;47:703–14.CrossRefPubMedPubMedCentral Greiner KA, Daley CM, Epp A, James A, Yeh H-W, Geana M, et al. Implementation intentions and colorectal screening screening: a randomized trial in safety-net clinics. Am J Prev Med. 2014;47:703–14.CrossRefPubMedPubMedCentral
Metadata
Title
Higher satisfaction with an alternative collection device for stool sampling in colorectal cancer screening with fecal immunochemical test: a cross-sectional study
Authors
Hye Young Shin
Mina Suh
Kui Son Choi
Sang-Hyun Hwang
Jae Kwan Jun
Dong Soo Han
You Kyoung Lee
Jae Hwan Oh
Chan Wha Lee
Do-Hoon Lee
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4290-0

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine